| Literature DB >> 35887580 |
Mohd Adnan1, Deeba Shamim Jairajpuri2, Muskan Chaddha3, Mohd Shahnawaz Khan4, Dharmendra Kumar Yadav5, Taj Mohammad3, Abdelbaset Mohamed Elasbali6, Waleed Abu Al-Soud7,8, Salem Hussain Alharethi9, Md Imtaiyaz Hassan3.
Abstract
Oral squamous cell carcinoma (OSCC) is a major cause of death in developing countries because of high tobacco consumption. RAC-alpha serine-threonine kinase (AKT1) is considered as an attractive drug target because its prolonged activation and overexpression are associated with cancer progression and metastasis. In addition, several AKT1 inhibitors are being developed to control OSCC and other associated forms of cancers. We performed a screening of the IMPPAT (Indian Medicinal Plants, Phytochemistry and Therapeutics) database to discover promising AKT1 inhibitors which pass through various important filters such as ADMET (absorption, distribution, metabolism, excretion, and toxicity) properties, physicochemical properties, PAINS (pan-assay interference compounds) filters, PASS (prediction of activity spectra for substances) analysis, and specific interactions with AKT1. Molecules bearing admirable binding affinity and specificity towards AKT1 were selected for further analysis. Initially, we identified 30 natural compounds bearing appreciable affinity and specific interaction with AKT1. Finally, tuberosin and villosol were selected as potent and selective AKT1 inhibitors. To obtain deeper insights into binding mechanism and selectivity, we performed an all-atom molecular dynamics (MD) simulation and principal component analysis (PCA). We observed that both tuberosin and villosol strongly bind to AKT1, and their complexes were stable throughout the simulation trajectories. Our in-depth structure analysis suggested that tuberosin and villosol could be further exploited in the therapeutic targeting of OSCC and other cancers after further clinical validations.Entities:
Keywords: AKT1; drug discovery; molecular dynamics simulation; natural compounds; oral squamous cell carcinoma; personalized medicine; virtual screening
Year: 2022 PMID: 35887580 PMCID: PMC9322152 DOI: 10.3390/jpm12071083
Source DB: PubMed Journal: J Pers Med ISSN: 2075-4426
Top 30 hits against AKT1 and their docking scores.
| S. No. | Compound ID | Phytochemical Name | Affinity (kcal/mol) | pKi | Ligand Efficiency |
|---|---|---|---|---|---|
| 1. | 174880 | Lactupicrin | −10.1 | 7.41 | 0.34 |
| 2. | 120698 | Capnoidine | −10.0 | 7.33 | 0.37 |
| 3. | 308140 | Diospyrin | −10.0 | 7.33 | 0.36 |
| 4. | 101277405 | Arboreol | −10.0 | 7.33 | 0.36 |
| 5. | 104940 | Withanolide S | −9.9 | 7.26 | 0.39 |
| 6. | 3822 | Cubebol | −9.9 | 7.26 | 0.34 |
| 7. | 5315739 | N-Acetyldehydroanonaine | −9.8 | 7.19 | 0.43 |
| 8. | 20055371 | - | −9.7 | 7.11 | 0.40 |
| 9. | 14630495 | Tuberosin | −9.7 | 7.11 | 0.39 |
| 10. | 146680 | (2,2′-Binaphthalene)-5,5′,8,8′-tetrone, 1,1′-dihydroxy-6,6′-dimethyl- | −9.7 | 7.11 | 0.35 |
| 11. | 16745513 | 4-Hydroxysesamin | −9.7 | 7.11 | 0.36 |
| 12. | 5317297 | 5-(6,7-Dihydroxy-2-oxochromen-5-yl)-6,7-dihydroxychromen-2-one | −9.7 | 7.11 | 0.37 |
| 13. | 101746 | Sesamolin | −9.6 | 7.04 | 0.35 |
| 14. | 12309624 | Papaverrubine B | −9.6 | 7.04 | 0.34 |
| 15. | 196979 | Frangulin A | −9.6 | 7.04 | 0.32 |
| 16. | 2913 | Acora-4,10-diene | −9.5 | 6.97 | 0.43 |
| 17. | 73393 | Lagerine | −9.5 | 6.97 | 0.36 |
| 18. | 21723446 | Pseudostrychnine | −9.5 | 6.97 | 0.36 |
| 19. | 5316097 | Corylin | −9.5 | 6.97 | 0.39 |
| 20. | 329584 | 3,3′-Bisjuglone | −9.5 | 6.97 | 0.36 |
| 21. | 5281806 | Psoralidin | −9.5 | 6.97 | 0.38 |
| 22. | 119204 | Roemerine | −9.4 | 6.89 | 0.45 |
| 23. | 5320486 | Gomezine | −9.4 | 6.89 | 0.47 |
| 24. | 5459059 | Ribasine | −9.4 | 6.89 | 0.36 |
| 25. | 91572 | Phaseolin | −9.4 | 6.89 | 0.39 |
| 26. | 94577 | Cepharadione A | −9.3 | 6.82 | 0.40 |
| 27. | 101595 | Vomicine | −9.3 | 6.82 | 0.33 |
| 28. | 5320772 | Psoralenol | −9.3 | 6.82 | 0.37 |
| 29. | 5490819 | Villosol | −9.3 | 6.82 | 0.31 |
| 30. | 11438278 | Cryptodorine | −9.2 | 6.75 | 0.40 |
ADMET properties of the selected compounds.
| S. No. | Compound ID | Phytochemical | Absorption | Distribution | Metabolism | Excretion | Toxicity |
|---|---|---|---|---|---|---|---|
| GI Absorption (%) | BBB Permeation | ||||||
| 1. | 329584 | 3,3′-Bisjuglone | High | No | No | No | No |
| 2. | 5320772 | Psoralenol | High | No | Yes | No | No |
| 3. | 5459059 | Ribasine | High | Yes | Yes | No | No |
| 4. | 5490819 | Villosol | High | No | Yes | No | No |
| 5. | 12309624 | Papaverrubine B | High | Yes | Yes | No | No |
| 6. | 14630495 | Tuberosin | High | Yes | Yes | No | No |
PASS analysis and molecular structures of the selected compounds.
| S. No. | Phytochemical | Molecular Structure | Pa | Pi | Activity |
|---|---|---|---|---|---|
| 1. | 3,3′-Bisjuglone |
| 0866 | 0003 | Antimutagenic |
| 0879 | 0016 | Membrane integrity agonist | |||
| 0828 | 0009 | Antineoplastic | |||
| 0799 | 0006 | Kinase inhibitor | |||
| 0773 | 0007 | Caspase-3 stimulant | |||
| 2. | Psoralenol |
| 0704 | 0008 | Anticarcinogenic |
| 0631 | 0023 | Apoptosis agonist | |||
| 0535 | 0013 | Antimutagenic | |||
| 0564 | 0053 | Antineoplastic | |||
| 0506 | 0033 | Kinase inhibitor | |||
| 3. | Ribasine |
| 0878 | 0002 | Neurotransmitter uptake inhibitor |
| 0512 | 0005 | Antineoplastic alkaloid | |||
| 0474 | 0023 | Caspase-8 stimulant | |||
| 0345 | 0079 | Caspase-3 stimulant | |||
| 0276 | 0029 | Antineoplastic (lymphoma) | |||
| 4. | Villosol |
| 0993 | 0001 | TP53 expression enhancer |
| 0902 | 0004 | Apoptosis agonist | |||
| 0854 | 0007 | Antineoplastic | |||
| 0662 | 0007 | Antineoplastic (breast cancer) | |||
| 0556 | 0006 | Prostate cancer treatment | |||
| 5. | Papaverrubine B |
| 0683 | 0029 | Antineoplastic |
| 0526 | 0028 | Antineoplastic (non-Hodgkin lymphoma) | |||
| 0503 | 0006 | Antineoplastic alkaloid | |||
| 0474 | 0009 | Antimitotic | |||
| 0376 | 0027 | Antineoplastic (lung cancer) | |||
| 6. | Tuberosin |
| 0792 | 0013 | Antineoplastic |
| 0770 | 0005 | Antineoplastic (breast cancer) | |||
| 0727 | 0021 | TP53 expression enhancer | |||
| 0627 | 0023 | Apoptosis agonist | |||
| 0571 | 0005 | Antineoplastic (ovarian cancer) |
Figure 1The schematic representation of the structure of AKT1 in a bound state with tuberosin and villosol. (A) Cartoon illustration of AKT1 with the elucidated molecules. (B) The representation of close interaction between AKT1 with tuberosin (red salmon) and villosol (purple). (C) The magnified illustration shows the surface potential view of the binding pocket of AKT1 with elucidated compounds.
Figure 2The two-dimensional representation of binding pocket residues of AKT1 and its respective interactions with compounds tuberosin (A) and villosol (B). The tuberosin shows the noncovalent interactions formed between the active site and ATP-binding residues of protein AKT1. The hydrogen bonds are formed between sites Lys179, Glu191, and Asp 292. The villosol shows noncovalent interactions between crucial residues of protein Glu234 and Asp292, with target protein AKT1.
Figure 3The structural dynamics of AKT1 after binding with tuberosin and villosol based on the function of time. (A) RMSD graph showing AKT1 when bound with tuberosin and villosol. (B) The average residual fluctuations (RMSF) graph of AKT1 is associated with tuberosin and villosol. The plots shown in the lower panels depict the probability distribution as PDF.
Figure 4The structural compactness of AKT1 when present with tuberosin and villosol binding as a function of time. (A) The radius of gyration (Rg) through time evaluation. (B) SASA plot of AKT1 as a function of time before and after binding with selected compounds. Lower graph plots depict the probability density function (PDF).
Figure 5Formation of hydrogen bonds in time evolution plot formed within 0.35 nm of intra-AKT1 (A). The probability density function (PDF) of the intramolecular hydrogen bonds present within the structure of AKT1 (B).
Figure 6The time evolution of intermolecular hydrogen bonds formed within 0.35 nm between AKT1 and tuberosin (A) and villosol (B). The panels on the lower side depict the probability density function distribution of H-bonds.
Figure 7The conformational sampling in principal compound analysis (PCA). The two-dimensional projections illustrate the conformational sampling of AKT1-tuberosin and AKT1-villosol complexes.
Figure 8The free energy landscapes (FELs) of (A) AKT1, (B) AKT1-tuberosin complex, and (C) AKT1-villosol complex.